Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	1152	1476	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
Liraglutide (1.8 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	Proinsulin : insulin ratio	20068	20228	Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16786	17277	At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Incidence of minor hypoglycaemia	25063	25283	Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	-1	-1	HbA1c decreased rapidly with all doses of liraglutide when added to glimepiride compared with either rosiglitazone or placebo (i.e. glimepiride monotherapy), irrespective of previous therapy. The greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3a?c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	Changes in calcitonin at week 26	25614	25802	No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	17434	17527	At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Fasting plasma glucose at week 26	17742	17887	An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P ≤ 0.006) after 26 weeks.
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	1152	1476	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18329	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).
Rosiglitazone plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	-1	-1	he greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3a?c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	-1	-1	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	-1	-1	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
Liraglutide (1.8 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20444	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	17434	17527	At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15381	15578	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (−0.4%) (Fig. 3d)
Liraglutide (0.6 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	15939	15991	Liraglutide 0.6 mg was non-inferior to rosiglitazone
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19283	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.
Liraglutide (all doses) plus glimepiride	Rosiglitazone plus glimepiride	Decreases in diastolic blood pressure	21734	21874	Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19282	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17145	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001)
Liraglutide (all doses) plus glimepiride	Rosiglitazone plus glimepiride	Changes in calcitonin at week 26	25614	25802	No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26.
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Postprandial plasma glucose	-1	-1	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15794	15938	All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	HOMA-B	20230	20444	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15794	15854	All liraglutide doses were superior to placebo (P < 0.0001),
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	-1	-1	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone. Rosiglitazone also was superior to placebo (P < 0.0001).
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19282	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	HOMA-IR	20445	20514	There were no significant differences between treatments for HOMA-IR.
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15381	15578	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (−0.4%) (Fig. 3d)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	15381	15567	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (−0.4%
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Incidence of minor hypoglycaemia	25063	25283	Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Incidence of minor hypoglycaemia	25063	25172	Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Incidence of minor hypoglycaemia	24623	25283	The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17145	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	17325	17741	By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg.
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	Decreases in diastolic blood pressure	21734	21874	Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	HOMA-IR	-1	-1	There were no significant differences between treatments for HOMA-IR.<NEWLINE> <NEWLINE><NEWLINE> <NEWLINE>Table 2
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	1477	1699	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	Reductions in systolic blood pressure	21541	21732	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Fasting plasma glucose at week 26	1152	1476	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	22056	22239	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	Decreases in diastolic blood pressure	-1	-1	Reductions in diastolic blood pressure also occurred with all treatments (0.7�??1.4 mmHg), with no significant differences between treatments.
Liraglutide (all doses) plus glimepiride	Rosiglitazone plus glimepiride	HOMA-IR	20445	20514	There were no significant differences between treatments for HOMA-IR.
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17277	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20443	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17183	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	-1	-1	Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5�??2.4 mmol/l; P < 0.0001)
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	851	1089	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	HOMA-B	20230	20443	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16565	17276	The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	15381	15578	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (−0.4%) (Fig. 3d)
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	HOMA-B	20230	20443	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)
Rosiglitazone plus glimepiride	Liraglutide plus glimepiride	Weight gain	19609	19875	Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (−2.3 to −1.4 kg; P < 0.0001), although there were no significant differences compared with placebo.
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	851	1010	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17183	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19283	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	18135	18329	The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	Proinsulin : insulin ratio	20068	20228	Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15794	15853	All liraglutide doses were superior to placebo (P < 0.0001)
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	851	1089	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18133	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	-1	-1	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001)
Rosiglitazone plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15993	16048	Rosiglitazone also was superior to placebo (P < 0.0001)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	22056	22240	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19093	19283	he percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	15381	15578	After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (−0.4%) (Fig. 3d)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17277	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	Reductions in systolic blood pressure	-1	-1	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6�??2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9�??2.3 mmHg).
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19282	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone
Liraglutide (0.6 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	15794	15992	All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20318	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05)
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	Pulse variations	22056	22143	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002).
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	-1	-1	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).<NEWLINE> <NEWLINE><NEWLINE> <NEWLINE>FIGURE 4
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	HOMA-B	20230	20444	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Incidence of minor hypoglycaemia	25063	25283	Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	Reductions in systolic blood pressure	-1	-1	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6�??2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9�??2.3 mmHg)
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	Reductions in systolic blood pressure	21541	21732	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)
Rosiglitazone plus glimepiride	Liraglutide plus glimepiride	Weight gain	1764	1987	Changes in body weight with liraglutide 1.8 mg (−0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (−0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg)
Rosiglitazone plus glimepiride	Liraglutide plus glimepiride	Weight gain	19609	19804	Unlike rosiglitazone, weight did not increase substantially with liraglutide and the differences between rosiglitazone and liraglutide were statistically significant (−2.3 to −1.4 kg; P < 0.0001)
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	21875	22240	Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Postprandial plasma glucose	18787	19036	Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.
Liraglutide (all doses) plus glimepiride	Rosiglitazone plus glimepiride	Decreases in diastolic blood pressure	-1	-1	Reductions in diastolic blood pressure also occurred with all treatments (0.7�??1.4 mmHg), with no significant differences between treatments.
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19260	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05)
Liraglutide (all doses) plus glimepiride	Rosiglitazone plus glimepiride	ADA postprandial plasma glucose goals less than 10.0 mmol/l	19092	19283	The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	Reductions in systolic blood pressure	21541	21733	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	Proinsulin : insulin ratio	20068	20228	Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02)
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	1477	1699	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)
Liraglutide (1.8 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20318	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05)
Liraglutide (all doses) plus glimepiride	Placebo plus glimepiride	Pulse variations	22056	22240	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Postprandial plasma glucose	-1	-1	Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Incidence of minor hypoglycaemia	25063	25172	Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	22056	22142	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002)
Liraglutide (1.8 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	Reductions in systolic blood pressure	21541	21733	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17277	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (0.6 mg) plus glimepiride	Rosiglitazone plus glimepiride	HbA1c level at 26 weeks	15792	15992	. All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18134	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	851	1009	Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	Proinsulin : insulin ratio	20068	20228	Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	18787	18910	Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	17434	17528	At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001),
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20319	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Incidence of minor hypoglycaemia	24623	25283	The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	22056	22240	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01).
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	Proinsulin : insulin ratio	20068	20319	Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02). HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),
Rosiglitazone plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15993	16049	Rosiglitazone also was superior to placebo (P < 0.0001).
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17277	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18134	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).
Liraglutide (1.8 mg) plus glimepiride	Liraglutide (1.2 mg) plus glimepiride	Patients reaching HbA1c goals less than 7.0% 	16950	17277	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18329	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	Reductions in systolic blood pressure	-1	-1	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6�??2.8 mmHg), they were not significantly different from placebo
Liraglutide (1.8 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	Reductions in systolic blood pressure	-1	-1	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6�??2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9�??2.3 mmHg).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16950	17184	The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Incidence of minor hypoglycaemia	24623	25283	The proportion of subjects experiencing minor hypoglycaemia during the trial was lowest with placebo (i.e. glimepiride monotherapy 2.6%; 0.17 events/subject-year), comparable with liraglutide 0.6 mg (5.2%, 0.17 events/subject-year) and rosiglitazone (4.3%, 0.12 events/subject-year) groups and similar between the liraglutide 1.2 mg (9.2%, 0.51 events/subject-year) and liraglutide 1.8 mg (8.1%, 0.47 events/subject-year) treatment groups. Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	HOMA-B	20230	20404	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01)
Liraglutide (1.2 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20444	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	21875	22142	Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Postprandial plasma glucose	18787	19036	Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone.
Liraglutide (1.8 mg) plus glimepiride 	Placebo plus glimepiride 	Reductions in systolic blood pressure	21541	21733	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	17434	17613	At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone.
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18078	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001)
Liraglutide (1.8 mg) plus glimepiride	Liraglutide (1.2 mg) plus glimepiride	Patients reaching HbA1c goals less than 7.0% 	16786	17277	At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Fasting plasma glucose at week 26	1152	1476	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).
Liraglutide (1.2 mg) plus glimepiride	Rosiglitazone plus glimepiride	Pulse variations	22056	22239	Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16786	16939	At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8% and 4% for placebo
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18134	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5%	16565	17276	The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	17434	17527	At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	1152	1404	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l)
Liraglutide (1.2 mg) plus glimepiride	Placebo plus glimepiride	Incidence of minor hypoglycaemia	25063	25230	Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048),
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	Fasting plasma glucose at week 26	17325	17887	By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg. An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P ≤ 0.006) after 26 weeks.
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18133	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)
Liraglutide (1.2 mg) plus glimepiride 	Placebo plus glimepiride 	Reductions in systolic blood pressure	21541	21733	Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).
Liraglutide (1.8 mg) plus glimepiride 	Rosiglitazone plus glimepiride 	HOMA-B	20230	20319	HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15794	15854	All liraglutide doses were superior to placebo (P < 0.0001),
Liraglutide (1.8 mg) plus glimepiride	Rosiglitazone plus glimepiride	ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l	17889	18328	The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%). The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively)
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	Fasting plasma glucose at week 26	1152	1404	Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l)
Liraglutide (0.6 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	-1	-1	Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).
Liraglutide (1.8 mg) plus glimepiride	Placebo plus glimepiride	HbA1c level at 26 weeks	15794	15938	All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).
